The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Breast Diseases

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Breast Diseases


High impact information on Breast Diseases


Chemical compound and disease context of Breast Diseases

  • Estrogen replacement therapy and benign breast disease [10].
  • We concluded that oral contraceptives reduced the incidence of benign breast disease, but that use of steroid hormones is ill-advised for women with already established benign breast disease [11].
  • Because cholesterol 5,6-epoxides have been reported to be mutagenic, carcinogenic, and cytotoxic, we investigated the relationship of these substances in breast fluid to histopathologically defined breast disease [12].
  • PURPOSE: Gemcitabine has promising single-agent activity in advanced breast disease [13].
  • This elevation in phosphocreatine plus a parallel elevation in an uncharacterized phosphate resonating at a chemical shift of 3.66 delta permits the important differentiation between malignancy and benignancy in human breast disease [14].

Biological context of Breast Diseases


Anatomical context of Breast Diseases


Gene context of Breast Diseases

  • Specifically and more directly, an association was also observed between the presence of a PTEN mutation and malignant breast disease [25].
  • In conclusion, TP53 gene mutation of the primary tumor is helpful in predicting the response of patients with metastatic breast disease to tamoxifen therapy [26].
  • Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study [27].
  • Together these experiments indicate that TGFalpha and the EGFR signaling pathway are potentially amenable to therapies for treatment of human breast disease [28].
  • Our data demonstrate that KDR activation is enhanced in breast cancer in vivo and emphasize the functional role of VEGF and KDR in the development of malignant breast disease [29].

Analytical, diagnostic and therapeutic context of Breast Diseases

  • Enzyme immunoassays were developed with the new antibodies and evaluated for their ability to discriminate between sera from breast cancer patients and from controls with benign breast disease [30].
  • We have used the MCF10AT xenograft model of human proliferative breast disease to examine the early effects of estradiol exposure on morphological progression of preneoplastic lesions and to define the step(s) in the morphological sequence at which estrogen may act [31].
  • The relation between methylxanthine consumption and biopsied benign breast disease was investigated by using data from a case-control study which included 1,569 cases and 1,846 controls identified between 1973 and 1980 through a nationwide screening program [32].
  • The percentage of free oestradiol was found to be highest in women with breast cancer, lowest in the control group and intermediate for the women with benign breast disease [33].
  • METHODS AND RESULTS: The present study addresses this issue by using cytokeratin 19 mRNA detection by reverse transcription-polymerase chain reaction (RT-PCR) in preoperative and postoperative blood samples from 54 patients undergoing excisional biopsy for benign breast disease; 22 healthy volunteers represented the control group [34].


  1. A population-based case-control study of thyroid cancer. Ron, E., Kleinerman, R.A., Boice, J.D., LiVolsi, V.A., Flannery, J.T., Fraumeni, J.F. J. Natl. Cancer Inst. (1987) [Pubmed]
  2. Biochemical characterization and crystalization of human Zn-alpha2-glycoprotein, a soluble class I major histocompatibility complex homolog. Sánchez, L.M., López-Otín, C., Bjorkman, P.J. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  3. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. Stark, A., Hulka, B.S., Joens, S., Novotny, D., Thor, A.D., Wold, L.E., Schell, M.J., Melton, L.J., Liu, E.T., Conway, K. J. Clin. Oncol. (2000) [Pubmed]
  4. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Tanaka, A., Furuya, A., Yamasaki, M., Hanai, N., Kuriki, K., Kamiakito, T., Kobayashi, Y., Yoshida, H., Koike, M., Fukayama, M. Cancer Res. (1998) [Pubmed]
  5. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. Tan-Chiu, E., Wang, J., Costantino, J.P., Paik, S., Butch, C., Wickerham, D.L., Fisher, B., Wolmark, N. J. Natl. Cancer Inst. (2003) [Pubmed]
  6. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. Rohan, T.E., Hartwick, W., Miller, A.B., Kandel, R.A. J. Natl. Cancer Inst. (1998) [Pubmed]
  7. Serum steroid binding proteins and the bioavailability of estradiol in relation to breast diseases. Langley, M.S., Hammond, G.L., Bardsley, A., Sellwood, R.A., Anderson, D.C. J. Natl. Cancer Inst. (1985) [Pubmed]
  8. Use of circulating pregnancy-specific beta 1 glycoprotein as a marker in carcinoma of the breast in women. Rosen, S.W., Gail, M.H., Tormey, D.C. J. Natl. Cancer Inst. (1982) [Pubmed]
  9. Human tissue polypeptide antigen in breast cancer. Nemoto, T., Constantine, R., Chu, T.M. J. Natl. Cancer Inst. (1979) [Pubmed]
  10. Estrogen replacement therapy and benign breast disease. Trapido, E.J., Brinton, L.A., Schairer, C., Hoover, R. J. Natl. Cancer Inst. (1984) [Pubmed]
  11. Oral contraceptives as related to cancer and benign lesions of the breast. Fasal, E., Paffenbarger, R.S. J. Natl. Cancer Inst. (1975) [Pubmed]
  12. Breast fluid cholesterol and cholesterol beta-epoxide concentrations in women with benign breast disease. Wrensch, M.R., Petrakis, N.L., Gruenke, L.D., Miike, R., Ernster, V.L., King, E.B., Hauck, W.W., Craig, J.C., Goodson, W.H. Cancer Res. (1989) [Pubmed]
  13. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. Pérez-Manga, G., Lluch, A., Alba, E., Moreno-Nogueira, J.A., Palomero, M., García-Conde, J., Khayat, D., Rivelles, N. J. Clin. Oncol. (2000) [Pubmed]
  14. 31P magnetic resonance spectroscopic profiles of neoplastic human breast tissues. Merchant, T.E., Gierke, L.W., Meneses, P., Glonek, T. Cancer Res. (1988) [Pubmed]
  15. Biallelic expression of the IGF2 gene in human breast disease. McCann, A.H., Miller, N., O'Meara, A., Pedersen, I., Keogh, K., Gorey, T., Dervan, P.A. Hum. Mol. Genet. (1996) [Pubmed]
  16. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice. Rose-Hellekant, T.A., Sandgren, E.P. Oncogene (2000) [Pubmed]
  17. Inadequate corpus luteal function in women with benign breast diseases. Sitruk-ware, L.R., Sterkers, N., Mowszowicz, I., Mauvais-Jarvis, P. J. Clin. Endocrinol. Metab. (1977) [Pubmed]
  18. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Kittiniyom, K., Mastronardi, M., Roemer, M., Wells, W.A., Greenberg, E.R., Titus-Ernstoff, L., Newsham, I.F. Genes Chromosomes Cancer (2004) [Pubmed]
  19. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Chui, X., Egami, H., Yamashita, J., Kurizaki, T., Ohmachi, H., Yamamoto, S., Ogawa, M. Br. J. Cancer (1996) [Pubmed]
  20. Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases. O'Neill, J.S., Miller, W.R. Br. J. Cancer (1987) [Pubmed]
  21. Human relaxins in normal, benign and neoplastic breast tissue. Tashima, L.S., Mazoujian, G., Bryant-Greenwood, G.D. J. Mol. Endocrinol. (1994) [Pubmed]
  22. Quantitative cytochemistry of glucose-6-phosphate dehydrogenase in benign and malignant breast tumours. Barron, E.T., Smyth, P.P., McDermott, E.W., Tobbia, I.N., Higgins, N.J. Eur. J. Cancer (1991) [Pubmed]
  23. Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. Bánkfalvi, A., Ludwig, A., De-Hesselle, B., Buerger, H., Buchwalow, I.B., Boecker, W. Mod. Pathol. (2004) [Pubmed]
  24. Effect of halothane and nitrous oxide anaesthesia on natural killer lymphocytes from patients with benign and malignant breast disease. Griffith, C.D., Kamath, M.B. British journal of anaesthesia. (1986) [Pubmed]
  25. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Marsh, D.J., Coulon, V., Lunetta, K.L., Rocca-Serra, P., Dahia, P.L., Zheng, Z., Liaw, D., Caron, S., Duboué, B., Lin, A.Y., Richardson, A.L., Bonnetblanc, J.M., Bressieux, J.M., Cabarrot-Moreau, A., Chompret, A., Demange, L., Eeles, R.A., Yahanda, A.M., Fearon, E.R., Fricker, J.P., Gorlin, R.J., Hodgson, S.V., Huson, S., Lacombe, D., Eng, C. Hum. Mol. Genet. (1998) [Pubmed]
  26. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Berns, E.M., Foekens, J.A., Vossen, R., Look, M.P., Devilee, P., Henzen-Logmans, S.C., van Staveren, I.L., van Putten, W.L., Inganäs, M., Meijer-van Gelder, M.E., Cornelisse, C., Claassen, C.J., Portengen, H., Bakker, B., Klijn, J.G. Cancer Res. (2000) [Pubmed]
  27. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Wong, S.Y., Purdie, A.T., Han, P. Am. J. Pathol. (1992) [Pubmed]
  28. Transforming growth factor alpha and mouse models of human breast cancer. Humphreys, R.C., Hennighausen, L. Oncogene (2000) [Pubmed]
  29. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Kranz, A., Mattfeldt, T., Waltenberger, J. Int. J. Cancer (1999) [Pubmed]
  30. Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Linsley, P.S., Brown, J.P., Magnani, J.L., Horn, D. Cancer Res. (1988) [Pubmed]
  31. Direct action of estrogen on sequence of progression of human preneoplastic breast disease. Shekhar, M.P., Nangia-Makker, P., Wolman, S.R., Tait, L., Heppner, G.H., Visscher, D.W. Am. J. Pathol. (1998) [Pubmed]
  32. Methylxanthines and benign breast disease. Schairer, C., Brinton, L.A., Hoover, R.N. Am. J. Epidemiol. (1986) [Pubmed]
  33. Serum oestradiol in women with and without breast disease. Bennett, I.C., McCaffrey, J.F., McCaffrey, E., Wyatt, B. Br. J. Cancer (1990) [Pubmed]
  34. Detection of circulating epithelial cells after surgery for benign breast disease. Crisan, D., Ruark, D.S., Decker, D.A., Drevon, A.M., Dicarlo, R.G. Mol. Diagn. (2000) [Pubmed]
WikiGenes - Universities